UK Markets open in 6 hrs

Valneva SE American Depositary Shares (VALN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
64.55+17.02 (+35.81%)
At close: 04:00PM EST
64.55 0.00 (0.00%)
After hours: 06:38PM EST

Valneva SE American Depositary Shares

6 rue Alain Bombard
Saint-Herblain 44800
France
33 2 28 07 37 10
http://valneva.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees700

Key executives

NameTitlePayExercisedYear born
Mr. Thomas LingelbachChairman of the Management Board, Pres & CEO761.56kN/A1963
Mr. Franck Grimaud MBAPres, Chief Bus. Officer & Member of Management Board479.2kN/A1967
Mr. David LawrenceActing Chief Financial Officer1.35MN/A1963
Mr. Frederic JacototVP of Legal & IP, Gen. Counsel, Corp. Sec. and Member of Management Board364.33kN/A1965
Dr. Juan-Carlos Jaramillo M.D.Chief Medical Officer & Member of the Management Board385.34kN/A1971
Mr. Perry CelentanoInterim Chief Operating OfficerN/AN/AN/A
Mr. Joshua Drumm Ph.D.VP Investor RelationsN/AN/AN/A
Ms. Laetitia Bachelot-FontaineVP Global Communications & European Investor RelationsN/AN/AN/A
Mr. Gerald StrohmaierVP of Human ResourceN/AN/AN/A
Mr. Christian TaucherHead of Global Medical AffairsN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium. The company also develops VLA15, a vaccine candidate that is in Phase II clinical trial against Borrelia; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; and VLA2001, a vaccine candidate that has completed Phase I/II clinical trial against SARS-CoV-2. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. The company has collaborations with Pfizer to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. Valneva SE was incorporated in 1999 and is headquartered in Saint-Herblain, France.

Corporate governance

Valneva SE American Depositary Shares’s ISS governance QualityScore as of 1 July 2021 is 10. The pillar scores are Audit: 10; Board: 8; Shareholder rights: 6; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.